Navigation

2004/034 NICE issues guidance on use of clopidogrel for acute coronary syndrome

The National Institute for Clinical Excellence (NICE) has issued guidance to the NHS in England and Wales on the use of clopidogrel for the treatment of non-ST-segment-elevation acute coronary syndrome (ACS). Clopidogrel is an anti-clotting drug which is licensed for use in combination with aspirin for the treatment of individuals suffering from unstable angina or non-ST-segment-elevation (NSTEMI) ACS. The guidance recommends that clopidogrel, together with low does aspirin, should be used for people with non-ST-segment-elevation ACS who have a moderate to high risk of a major heart attack or death.

This page was last updated: 16 September 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.